Ben Wong1, Deborah Zimmerman2, Frances Reintjes3, Mark Courtney1, Scott Klarenbach1, Graeme Dowling4, Robert P Pauly5. 1. Division of Nephrology and Transplant Immunology, University of Alberta, Edmonton, Alberta. 2. Division of Nephrology, University of Ottawa, Ottawa, Ontario. 3. Northern Alberta Renal Program, Alberta Health Services, Alberta, Canada. 4. Office of the Chief Medical Examiner, Province of Alberta; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada. 5. Division of Nephrology and Transplant Immunology, University of Alberta, Edmonton, Alberta. Electronic address: robert.pauly@ualberta.ca.
Abstract
BACKGROUND: There has been resurgent interest in home hemodialysis (HD) in recent years because of the reported benefits and its excellent safety record. However, the potential for adverse events, including potentially catastrophic ones, exists when patients are performing HD in their homes without supervision. There is a lack of literature on this important topic. STUDY DESIGN: Quality improvement report. SETTING & PARTICIPANTS: We present the experience of 2 adult home HD programs in Canada from 2001 to 2012, including a total of 190 patients and approximately 500 patient-years of treatments. QUALITY IMPROVEMENT PLAN: We retrospectively reviewed all life-threatening adverse events occurring in our programs and re-examined our approach to patient training, retraining, and safety monitoring. RESULTS: We report 1 death and 6 potentially fatal adverse events, yielding a crude rate of 0.060 events/1,000 dialysis treatments. Six of 7 events involved significant blood loss (including 1 exsanguination); 5 of 7 events involved human error with lapses in protocol adherence. Because such events are rare, evaluation of specific intervention strategies will require much longer follow-up. LIMITATIONS: Retrospective identification of cases. A specific quality improvement initiative was not undertaken. CONCLUSIONS: Life-threatening adverse events in home HD are uncommon; however, when one does occur, this should prompt review of home HD-related policies and procedures to make this therapy even safer.
BACKGROUND: There has been resurgent interest in home hemodialysis (HD) in recent years because of the reported benefits and its excellent safety record. However, the potential for adverse events, including potentially catastrophic ones, exists when patients are performing HD in their homes without supervision. There is a lack of literature on this important topic. STUDY DESIGN: Quality improvement report. SETTING & PARTICIPANTS: We present the experience of 2 adult home HD programs in Canada from 2001 to 2012, including a total of 190 patients and approximately 500 patient-years of treatments. QUALITY IMPROVEMENT PLAN: We retrospectively reviewed all life-threatening adverse events occurring in our programs and re-examined our approach to patient training, retraining, and safety monitoring. RESULTS: We report 1 death and 6 potentially fatal adverse events, yielding a crude rate of 0.060 events/1,000 dialysis treatments. Six of 7 events involved significant blood loss (including 1 exsanguination); 5 of 7 events involved human error with lapses in protocol adherence. Because such events are rare, evaluation of specific intervention strategies will require much longer follow-up. LIMITATIONS: Retrospective identification of cases. A specific quality improvement initiative was not undertaken. CONCLUSIONS: Life-threatening adverse events in home HD are uncommon; however, when one does occur, this should prompt review of home HD-related policies and procedures to make this therapy even safer.
Authors: Damien Ashby; Natalie Borman; James Burton; Richard Corbett; Andrew Davenport; Ken Farrington; Katey Flowers; James Fotheringham; R N Andrea Fox; Gail Franklin; Claire Gardiner; R N Martin Gerrish; Sharlene Greenwood; Daljit Hothi; Abdul Khares; Pelagia Koufaki; Jeremy Levy; Elizabeth Lindley; Jamie Macdonald; Bruno Mafrici; Andrew Mooney; James Tattersall; Kay Tyerman; Enric Villar; Martin Wilkie Journal: BMC Nephrol Date: 2019-10-17 Impact factor: 2.388
Authors: Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood Journal: Clin J Am Soc Nephrol Date: 2022-03-02 Impact factor: 10.614
Authors: Annie-Claire Nadeau-Fredette; Carmel Hawley; Elaine Pascoe; Christopher T Chan; Martine Leblanc; Philip A Clayton; Kevan R Polkinghorne; Neil Boudville; David W Johnson Journal: Perit Dial Int Date: 2015-11-02 Impact factor: 1.756
Authors: Robert P Pauly; Paul Komenda; Christopher T Chan; Michael Copland; Azim Gangji; David Hirsch; Robert Lindsay; Martin MacKinnon; Jennifer M MacRae; Philip McFarlane; Gihad Nesrallah; Andreas Pierratos; Martin Plaisance; Frances Reintjes; Jean-Philippe Rioux; John Shik; Andrew Steele; Rod Stryker; George Wu; Deborah L Zimmerman Journal: Can J Kidney Health Dis Date: 2014-06-10
Authors: Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum Journal: Crit Care Date: 2021-06-10 Impact factor: 9.097